Reboxetine: the first selective noradrenaline re-uptake inhibitor

Bibliography

• KESSLER RC, MCGONAGLE KA, ZHAO S et al Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiat. (1994) 51:8–19.
   PubMed Web of Science ®Google Scholar
• LEPINE JP, GASTPAR M, MENDLEWICZ J, TYLEE A ON BEHALF OF THE DEPRES STEERING COMMITTEE: Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. (1997) 12:19–29.
   PubMed Web of Science ®Google Scholar
• HIRSCHFELD RMA, MONTGOMERY SA, KELLER M et al.: Social functioning in depression: a review. J. Clin. Psychiat. (2000) (In Press).
   Google Scholar
• ••Comprehensive overview of the relationship betweenpsychosocial impairment and depressive disorders and the efficacy of currently available antidepressants.
   Google Scholar
• PAYKEL ES, WEISSMAN MM: Social adjustment and depression. A longitudinal study. Arch. Gen. Psychiat. (1973) 28:659–663.
   PubMed Web of Science ®Google Scholar
• KASPER S: Treatment benefits of reboxetine. Int. J. Psychiat. Clin. Prac. (1999) 3\(Suppl. 1):53–58.
   Google Scholar
• •Comprehensive overview of the efficacy of reboxetine for treatment of depression as well as social functioning.
   Google Scholar
• RIVA M, BRUNELLO N, ROVESCALLI AC et al.: Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J. Drug Dev. (1989) 1(4):243–253.
   Google Scholar
• STROLIN BENEDETTI M, PELLIZZONI C, POGESSI I et al.: Pharmacokinetics of reboxetine enantiomers in healthy volunteers. XIIth International Congress of Pharmacology. Montreal, Canada (24–29 July 1994). Abstract no. 13.21.17.
   Google Scholar
• DOSTERT P, STROLIN BENEDETTI M, POGESSI I: Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur. Neuropharmacol. (1997) 7\(Suppl. 1):523–535.
   Google Scholar
• •Thorough overview of the pharmacokinetics of reboxetine.
   Google Scholar
• EDWARDS DMF, PELLIZONI C, BREUL HP et al.: Pharma-cokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm. Drug Dispos. (1995) 16:443–460.
   PubMedGoogle Scholar
• PELLIZZONI C, STROLIN BENEDETTI M, POGGESI E, FRIGERIO E, TOON S, LANGLEY SJ: Pharmacokinetics of reboxetine in healthy volunteers: relative bioavail-ability and food effect. Pharmacol. Res. (1995) 31 (Suppl.):41.
   Google Scholar
• FLEISHAKER JC, MUCCI M, PELLIZZONI C, POGGESI I: Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm. Drug Dispos. (1999) 20:53–57.
   PubMed Web of Science ®Google Scholar
• JANNUZZO MG, STROLIN BENEDETTI M, DUCHENE P, DUBINI A, DOSTERT P: Pharmacokinetics of reboxetine in the elderly. Advances in simultaneous pharmacold-neticipharrnacodynamic modelling [abstract]. 2nd International Symposium. Measurement and Kinetics of In vivo Drug Effects. Noordwijkerhout, The Netherlands (14–16 April 1994) 94–96.
   Google Scholar
• FIORENTINI F, POGGESI I, JANNUZZO MG, DUCHENE P, STROLIN BENEDETTI M: Pharmacokinetics of reboxetine, a new selective noradrenaline uptake inhibitor, in patients with various degrees of hepatic and renal insufficiency. Pharmacol Res (1997) 35(3):239.
   Google Scholar
• NEMEROFF CB, DEVANE CL, POLLOCK BG: Newer antidepressants and the cytochrome P450 system. Am. J. Psychiat. (1996) 153:311–319.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA: Reboxetine: additional benefits to the depressed patient. J. Psychopharmacol. (1997) 11\(Suppl. 4):S9–S15.
   Google Scholar
• MONTGOMERY SA, ANGST J, BULLER R et al.: Report of a consensus meeting. Clinical relevance of response and improvement in psychopharrnacology. Eur. Neuropsychopharmacol. (1995) 5:531–533.
   Google Scholar
• BERZEWSKI H, VAN MOFFAERT M, GAGIANO CA: Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur. Neurop-sychopharmacol. (1997) 7\(Suppl. 1):547–553.
   Google Scholar
• ••Large-scale comparison with the TCA imipramine.
   Google Scholar
• MASSANA J, MOLLER HJ, BURROWS GD, MONTENEGRO RM: Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int. Clin. Psychopharmacol. (1999) 14(2):73–80.
   PubMedGoogle Scholar
• ••Large-scale comparison with the SSRI fluoxetine.
   Google Scholar
• ANDERSON IM, TOMENSON BM: The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepres-sants. J. Psychopharmacol. (1994) 8:238–249.
   PubMed Web of Science ®Google Scholar
• KASPER S, FUGER J, MOLLER HJ: Comparative efficacy of antidepressants. Drugs (1992) 43:11–23.
   PubMedGoogle Scholar
• KASPER S: Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J. Clin. Psychopharmacol. (1997) 17:10S–28S.
   Google Scholar
• NEIRENBERG AA: The treatment of severe depression: is there an efficacy gap between SSRI and TCA antide-pressant generation. J. Clin. Psychiat. (1994) 9:55–59.
   Google Scholar
• DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Citaloprarn: clinical effect profile in comparison with clomipramine. A controlled multi-center study. Psychopharmacology (1986) 90:131–138.
   PubMed Web of Science ®Google Scholar
• DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multi-center study. J. Affect. Dis. (1990) 18:289–299.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA: Managing the severely ill and long-term depressed. Int. J. Psychiat. Clin. Prac. (1999) 3\(Suppl. 1):S13–S17.
   Google Scholar
• VERSIANI M, MEHILANE L, GASZNER P, ARNAUD-CASTIGLIONI R: Reboxetine, a unique selective NIU, prevents relapse and recurrence in long-term treatment of major depressive disorder. J. Clin. Psychiat. (1999) 60(6):400–406.
   PubMedGoogle Scholar
• ••Detailed presentation of the efficacy of reboxetine in thelong-term treatment of depression.
   Google Scholar
• BOSC M, DUBINI A, POLIN V: Development and valida- tion of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur. Neuropsychopharmacol. (1997) 7\(Suppl. 1):S57–S70.
   Google Scholar
• DUBINI A, BOSC M, POLIN V: Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur. Neuropsychopharmacol. (1997a) 7\(Suppl. 1):S49–S55.
   Google Scholar
• ••Detailed examination of the effect of two classes of antide-pressant on social functioning.
   Google Scholar
• DUBINI A, BOSC M, POLIN V: Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning./ Psychophar-macol. (1997b) 11\(Suppl. 4):S17–S23.
   Google Scholar
• ••Detailed examination of the effect of two classes of antide-pressant on social functioning.
   Google Scholar
• KATONA C, BERCOFF E, CHIU E, TACK P, VERSIANI M, WOELK H: Reboxetine versus irnipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J. Affect. Dis. (1999) 55(2–3)203–213.
   Google Scholar
• ••Large-scale comparison in elderly patients.
   Google Scholar
• HILGER E, WILLEIT M, PRASCHAK-REIDER N et al.:Reboxetine in seasonal affective disorder. Biol. Psychiat. (1999) 45:77s.
   Google Scholar
• EL GIAMAL N, STRNAD A, KASPER S, DE ZWAAN M, BAILER U, LENNK C: Open trial of reboxetine in the treatment of bulimia nervosa (BN) [abstract]. XI World Congress of Psychiatry. Hamburg, Germany. (6–11 August 1999).
   Google Scholar
• MUCCI M: Reboxetine: a review of antidepressant tolerability. J. Psychopharmacol. (1997) 11\(Suppl. 4):S33–S37.
   Google Scholar
• ••Thorough overview of the tolerability of reboxetine indepressed adult and elderly patients.
   Google Scholar
• BALD WIN D, HAWLEY C, SZABADI E et al.: Reboxetine in the treatment of depression: early clinical experience in the UK. Int. J. Psychiat. Clin. Prac. (1998) 2:195–201.
   PubMedGoogle Scholar
• •First report of the utility of reboxetine in general practice.
   Google Scholar
• MONTGOMERY SA: Reboxetine: a new antidepressant therapy. Prescriber (April 1998) 116–119.
   Google Scholar
• HINDMARCH I. Effect of antidepressants on cognitive and psychomotor function: the lack of effect of reboxetine. Hum. Psychopharmacol. (1998) 13:S21–S27.
   Google Scholar
• HERRMANN WM, FUDER H: Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance in healthy subjects. Hum. Psychopharmacol. (1998) 13(6):425–433.
   Google Scholar
• HOLM KJ: Reboxetine: a review of its use in depression. CNS Drugs (1999) 12(1):65–83.
   Google Scholar
• ••Comprehensive overview of the reboxetine in the treatmentof depression.
   Google Scholar